Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Part of paid clinical trials in Miami, Florida.

Sponsor
Jose Lutzky, MD
Study ID
NCT04552223
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Uveal Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
  • Relatlimab — DRUG
    Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.

Study Details

The purpose of this research is to test if a combination treatment of nivolumab and relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.

Key Dates

Start date
Nov 10, 2020
Status verified
Jan 2026
Primary completion
Jan 4, 2024
Completion
Jan 4, 2026

Study Design

Enrollment
27 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab Plus Relatlimab Group
    Participants in this group will receive Nivolumab and Relatlimab administered together on Day 1 of every 4 week cycle. Both drugs will be administered until disease progression or intolerable toxicity for up to 24 months.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Miami Sylvester Comprehensive Cancer CenterMiamiFlorida33136-

Related coverage on Hipa.ai

Find similar trials in Miami, FL

By research site
University of Miami Sylvester Comprehensive Cancer Center· Miami, FL

Related Studies